IM Cannabis Corp. (NASDAQ: IMCC) is a micro-cap medical cannabis company headquartered in Israel that imports and distributes cannabis to patients and operates retail pharmacies and online platforms. Shares were trading at $0.45 at midday, down 16.67% from the previous session's close of $0.54, confirming a decisively negative move. The immediate reason cited by the market is the company's announcement that it will execute a 3-for-1 share consolidation on November 23 to support compliance with Nasdaq's $1.00 minimum bid price requirement, together with its disclosure that it is no longer eligible for a standard compliance period because it already completed a 30-for-1 consolidation on August 27, 2026.
The consolidation reduces issued shares from roughly 1,844,162 to about 614,721 at a 1-for-3 ratio. Mechanically, that lifts the quoted price — a $0.54 close becomes roughly $1.61 on paper. Investors, however, focused on the second half of the release: because IMCC effected a reverse split within the prior year, Nasdaq Listing Rule 5810(c)(3)(A)(iv) denies it the usual 180-calendar-day cure period. If the closing bid stays below $1.00 for 30 consecutive business days, Nasdaq staff would issue a Staff Delisting Determination. For a company that has now consolidated its shares four times in five years, the announcement reads less like a fix than a countdown, and the stock was sold accordingly.
The reverse split landed five days after third-quarter results that gave shareholders little to anchor on. Continuing-operations revenue fell to C$1.65 million from C$5.08 million, a gross loss of C$35,000 replaced a year-earlier gross profit of C$1.58 million, and the net loss widened to C$7.08 million from C$3.87 million. Nine-month losses reached C$13.93 million. Cash stood at C$2.4 million against total liabilities of C$16.7 million and a shareholders' deficit of C$2.99 million. With European operations sold off in late September, the remaining Israeli platform is small, loss-making, and reliant on external financing.
On November 4 the company closed a US$1.2 million convertible note with a 15% original issue discount, conversion at the lower of $0.610 or 85% of the lowest daily VWAP over the prior 20 sessions, and warrants on nearly 3.94 million shares — a sum more than double the current share count. Because conversion prices reset lower as the stock weakens, each tranche adds supply into a falling market. A large registered resale block filed in November reinforced the perception of persistent selling pressure.
Turnover was thin even by this stock's modest standards, with recent sessions averaging roughly 40,000 shares; a float that small turns modest sell orders into outsized percentage moves. The decline was issuer-specific and did not reflect a broad cannabis-sector move. Technically, the stock sits at the bottom of a violent downtrend: it closed at $4.23 on September 18 after a drone-acquisition rally briefly pushed it as high as $8.65 on enormous volume, and has lost more than 89% since. It is trading below every meaningful moving average and at the low end of a 52-week range of $0.45 to $62.40, with the November 16 all-time low now acting as the only visible reference point.
On a scale where 0 means no meaningful news and a normal price move, and 100 means transformative news and an extreme, rare move, IMCC scores 40 out of 100. The verified news was genuinely material for a company of this size: a reverse split tied to listing compliance, an explicit delisting warning, and a sharply smaller revenue base. The price behavior, however, was not extreme by the stock's own standards. The decline was roughly 1.8 times the typical daily move of about 9.3%, and sessions with equal or larger absolute moves occurred eight times in the last 60 trading days. Strong news paired with a routine-for-this-stock swing produces a mid-range score.
The November 23 effective date is the immediate checkpoint: post-consolidation trading begins at the open, and the market will quickly show whether the bid can hold above $1.00. A sustained sub-$1 print restarts the 30-business-day delisting clock. Also pending is the non-binding letter of intent to acquire 51% of Poland's Space Defense Innovations, a tactical drone reseller; no definitive agreement has been signed, and no assurance of completion exists. Fourth-quarter results, expected in the new year, will show whether the slimmed-down Israeli operation can stabilize revenue. Analysts provide minimal coverage, and the key risks are straightforward: further equity issuance, conversion-driven dilution, and exchange compliance.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and traded symbols, so the page offers a practical way to compare approaches side by side. For readers tracking volatile names like this one, reviewing the current leaders is a useful next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The RSI Oscillator for IMCC moved out of oversold territory on November 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 38 of the 41 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 66 cases where IMCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 162 of 192 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
IMCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMCC entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.070) is normal, around the industry mean (6.379). P/E Ratio (-0.006) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric